ModerateSNRI×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Duloxetine is a serotonin and noradrenaline reuptake inhibitor (SNRI). When duloxetine is combined with oral anticoagulants, the risk of bleeding may rise because of a pharmacodynamic interaction (duloxetine SmPC, EMA). Serotonin released by platelets is involved in haemostasis, and drugs that interfere with serotonin reuptake, duloxetine included, may increase the risk of bleeding, and anticoagulants may add to this risk (US duloxetine prescribing information, US Food and Drug Administration, FDA). The edoxaban SmPC warns that, as with other anticoagulants, SNRIs may raise the risk of bleeding through their reported effect on platelets (edoxaban SmPC, EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).
Symptoms
The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Bruising, purpura and gastrointestinal bleeding have been reported with selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors (SNRIs), duloxetine included (duloxetine SmPC, European Medicines Agency, EMA). Such bleeding has ranged from bruising, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (US duloxetine prescribing information, US Food and Drug Administration, FDA).
Management
The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Use caution when duloxetine is combined with oral anticoagulants and in patients with a known bleeding tendency (duloxetine SmPC, EMA). Warn the patient about the increased risk of bleeding when duloxetine is combined with drugs that affect coagulation (US duloxetine prescribing information, US Food and Drug Administration, FDA). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Cymbalta 30 mg cápsulas duras gastrorresistentes – ficha técnica (texto EMA en CIMA) (2026)– EMA SmPC vía AEMPS CIMA, nº 04296001 (EU/1/04/296), secciones 4.4 y 4.5
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- FDA: Duloxetine delayed-release capsules (duloxetine) prescribing information (2026)– FDA, DailyMed, Lupin Pharmaceuticals, setid 829a4f51-c882-4b64-81f3-abfb03a52ebe, revised 05/2026, sections 4, 5.2, 5.4, 5.5, 7.1–7.17 and 12.2
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2